Darwin AG Reports Doubling of Revenue in 2025

Darwin AG announced a significant financial milestone in 2025, with revenues more than doubling to EUR 54.3 million, compared to EUR 25.3 million the previous year. Net income closed positively at EUR 0.5 million, despite substantial investments in IT and business expansion. The company's core operations in genetic testing and personalized healthcare products remain strong contributors to growth.

Strategic partnerships and acquisitions, notably in the USA and UAE, alongside European expansion, have bolstered Darwin's presence in pharmaceuticals and medical devices. The company's acquisition of MEDICOPHARM AG further solidified its market position.

However, operating results (EBIT) showed a loss of EUR -10.8 million due to high investment costs associated with IT platform development. Despite these challenges, Darwin forecasts more than EUR 65 million in revenue for 2026. The geopolitical and economic environment poses uncertainties, but the company expects continued growth in genetic and personalized product sectors.